Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366064 | PMC |
| http://dx.doi.org/10.1186/s12876-025-04214-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modified pro re nata regimen of brolucizumab in treatment-naive neovascular age-related macular degeneration.
Retin Cases Brief Rep
October 2024
Eye Clinic, Humanitas-Gradenigo Hospital, Torino, Italy.
Purpose: To study the efficacy and safety of pro re nata regimen of brolucizumab, without loading dose, in treatment-naive patients with neovascular age-related macular degeneration (nAMD).
Case Series: Retrospective, observational study. We included all consecutive patients diagnosed with treatment- naïve nAMD undergoing Brolucizumab in Humanitas eye clinic, Turin, Italy between April 2022 and May 2023.
A Retrospective Multicenter Stratified Study on Perinatal Factors Influencing Neonatal Mortality in Preterm Infants in Kazakhstan.
Int J Pediatr
August 2025
Department of Neonatology, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
This study is aimed at evaluating the cumulative effect of postnatal risk factors on the survival of preterm neonates by examining key clinical parameters and complications across various gestational ages. A retrospective cohort study was conducted using data from 1109 neonates admitted to neonatal intensive care units at two tertiary regional hospitals in Kazakhstan between 2021 and 2024. Patients were classified into three groups based on gestational age: extremely preterm (< 28 weeks, = 223), very preterm (28-31 weeks, = 384), and moderate to late preterm (32-36 weeks, = 502).
View Article and Find Full Text PDFCRISPR and gene editing for kidney diseases: where are we?
Clin Kidney J
September 2025
Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Genome editing technologies, particularly clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, have transformed biomedical research by enabling precise genetic modifications. Due to its efficiency, cost-effectiveness and versatility, CRISPR has been widely applied across various stages of research, from fundamental biological investigations in preclinical models to potential therapeutic interventions. In nephrology, CRISPR represents a groundbreaking tool for elucidating the molecular mechanisms underlying kidney diseases and developing innovative therapeutic approaches.
View Article and Find Full Text PDFAnemia and iron deficiency in post-kidney transplantation: an unsolved challenge.
Clin Kidney J
September 2025
Prof Department of Advanced Medical and Surgical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Anemia and iron deficiency (ID) are common and significant complications in kidney transplant recipients (KTRs) that can affect their health-related quality of life (HRQoL) and outcomes. Current anemia guidelines equate the post-transplant situation with the anemia associated with chronic kidney disease (CKD) in non-transplanted persons, not acknowledging relevant differences ranging from pathophysiology to clinical manifestation. Nephrologists caring for these patients tend to pay less attention to post-transplant anemia (PTA) and ID than in non-transplanted persons with CKD.
View Article and Find Full Text PDFCorrection: The pivotal regulatory role of the FEV-SLC7A11 axis in ferroptosis elucidates the anti-aging mechanism of β-sitosterol in a cross-species study.
Front Pharmacol
August 2025
Department of Pathogenic Biology and Key Laboratory of Tropical Translational Medicine of Ministry of Education, School of Basic Medicine and Life Sciences, Hainan Medical University, Haikou, China.
[This corrects the article DOI: 10.3389/fphar.2025.
View Article and Find Full Text PDF